Dashboard
Manage Tickers

XNCRXencor Inc

Nasdaq xencor.com


$ 23.67 $ -0.58 (-2.39 %)    

Wednesday, 08-May-2024 15:59:31 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 439.55 $ -0.26 (-0.06 %)
DIA $ 390.50 $ 1.74 (0.45 %)
SPY $ 517.10 $ 0.05 (0.01 %)
TLT $ 90.18 $ -0.55 (-0.61 %)
GLD $ 213.58 $ -0.63 (-0.29 %)
$ 23.66
$ 23.91
$ 0.00 x 0
$ 0.00 x 0
$ 23.24 - $ 24.19
$ 16.49 - $ 28.96
621,810
na
1.43B
$ 0.67
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-29-2024 12-31-2023 10-K
2 11-07-2023 09-30-2023 10-Q
3 08-03-2023 06-30-2023 10-Q
4 05-08-2023 03-31-2023 10-Q
5 02-27-2023 12-31-2022 10-K
6 11-07-2022 09-30-2022 10-Q
7 08-03-2022 06-30-2022 10-Q
8 05-05-2022 03-31-2022 10-Q
9 02-24-2022 12-31-2021 10-K
10 11-08-2021 09-30-2021 10-Q
11 08-04-2021 06-30-2021 10-Q
12 05-05-2021 03-31-2021 10-Q
13 02-24-2021 12-31-2020 10-K
14 11-06-2020 09-30-2020 10-Q
15 08-05-2020 06-30-2020 10-Q
16 05-08-2020 03-31-2020 10-Q
17 02-25-2020 12-31-2019 10-K
18 11-05-2019 09-30-2019 10-Q
19 08-07-2019 06-30-2019 10-Q
20 05-09-2019 03-31-2019 10-Q
21 02-26-2019 12-31-2018 10-K
22 11-05-2018 09-30-2018 10-Q
23 08-07-2018 06-30-2018 10-Q
24 05-07-2018 03-31-2018 10-Q
25 02-28-2018 12-31-2017 10-K
26 11-08-2017 09-30-2017 10-Q
27 08-07-2017 06-30-2017 10-Q
28 05-10-2017 03-31-2017 10-Q
29 03-01-2017 12-31-2016 10-K
30 11-02-2016 09-30-2016 10-Q
31 08-03-2016 06-30-2016 10-Q
32 05-02-2016 03-31-2016 10-Q
33 03-08-2016 12-31-2015 10-K
34 11-04-2015 09-30-2015 10-Q
35 08-05-2015 06-30-2015 10-Q
36 05-05-2015 03-31-2015 10-Q
37 02-20-2015 12-31-2014 10-K
38 11-10-2014 09-30-2014 10-Q
39 08-01-2014 06-30-2014 10-Q
40 05-15-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

analyst-scoreboard-6-ratings-for-xencor
Analyst Scoreboard: 6 Ratings For Xencor
04/16/2024 18:02:38

btig-maintains-buy-on-xencor-lowers-price-target-to-38
BTIG Maintains Buy on Xencor, Lowers Price...
04/16/2024 16:04:43

BTIG analyst Kaveri Pohlman maintains Xencor (NASDAQ:XNCR) with a Buy and lowers the price target from $56 to $38.

xencor-appoints-bart-cornelissen-as-chief-financial-officer
Xencor Appoints Bart Cornelissen As Chief ...
04/09/2024 12:04:02

piper-sandler-downgrades-xencor-to-neutral-lowers-price-target-to-24
Piper Sandler Downgrades Xencor to Neutral...
02/28/2024 19:40:33

Piper Sandler analyst Edward Tenthoff downgrades Xencor (NASDAQ:XNCR) from Overweight to Neutral and lowers the price target...

unveiling-4-analyst-insights-on-xencor
Unveiling 4 Analyst Insights On Xencor
02/28/2024 16:01:12

rbc-capital-reiterates-outperform-on-xencor-maintains-32-price-target
RBC Capital Reiterates Outperform on Xenco...
02/28/2024 15:49:32

RBC Capital analyst Gregory Renza reiterates Xencor (NASDAQ:XNCR) with a Outperform and maintains $32 price target.

bmo-capital-maintains-outperform-on-xencor-lowers-price-target-to-34
BMO Capital Maintains Outperform on Xencor...
02/28/2024 14:23:26

BMO Capital analyst Etzer Darout maintains Xencor (NASDAQ:XNCR) with a Outperform and lowers the price target from $38 to $34.

wedbush-maintains-outperform-on-xencor-lowers-price-target-to-34
Wedbush Maintains Outperform on Xencor, Lo...
02/28/2024 12:56:28

Wedbush analyst David Nierengarten maintains Xencor (NASDAQ:XNCR) with a Outperform and lowers the price target from $36 to ...

recap-xencor-q4-earnings
Recap: Xencor Q4 Earnings
02/27/2024 21:15:25

xencor-q4-2023-gaap-eps-031-misses-009-estimate-sales-4469m-miss-7384m-estimate
Xencor Q4 2023 GAAP EPS $(0.31) Misses $(0...
02/27/2024 21:12:00

Xencor (NASDAQ:XNCR) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.09) by 2...

earnings-scheduled-for-february-27-2024
Earnings Scheduled For February 27, 2024
02/27/2024 10:01:31

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on rev...

earnings-preview-xencor
Earnings Preview: Xencor
02/26/2024 16:01:37

navigating-4-analyst-ratings-for-xencor
Navigating 4 Analyst Ratings For Xencor
01/22/2024 16:00:49

mizuho-maintains-buy-on-xencor-lowers-price-target-to-50
Mizuho Maintains Buy on Xencor, Lowers Pri...
01/22/2024 14:24:59

Mizuho analyst Mara Goldstein maintains Xencor (NASDAQ:XNCR) with a Buy and lowers the price target from $59 to $50.

guggenheim-maintains-buy-on-xencor-lowers-price-target-to-34
Guggenheim Maintains Buy on Xencor, Lowers...
11/08/2023 20:32:57

Guggenheim analyst Michael Schmidt maintains Xencor (NASDAQ:XNCR) with a Buy and lowers the price target from $40 to $34.

rbc-capital-maintains-outperform-on-xencor-lowers-price-target-to-32
RBC Capital Maintains Outperform on Xencor...
11/08/2023 20:15:27

RBC Capital analyst Gregory Renza maintains Xencor (NASDAQ:XNCR) with a Outperform and lowers the price target from $36 to $32.

wedbush-maintains-outperform-on-xencor-lowers-price-target-to-36
Wedbush Maintains Outperform on Xencor, Lo...
11/08/2023 14:16:35

Wedbush analyst David Nierengarten maintains Xencor (NASDAQ:XNCR) with a Outperform and lowers the price target from $37 to ...

xencor-sells-portion-of-royalties-and-milestones-from-ultomiris-and-monjuvi-to-omers-life-sciences-for-215m
Xencor Sells Portion Of Royalties And Mile...
11/07/2023 22:04:38

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the t...

recap-xencor-q3-earnings
Recap: Xencor Q3 Earnings
11/07/2023 21:11:19

xencor-q3-2023-gaap-eps-040-beats-073-estimate-sales-5916m-beat-2932m-estimate
Xencor Q3 2023 Gaap EPS $(0.40) Beats $(0....
11/07/2023 21:05:49

Xencor (NASDAQ:XNCR) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.73) by 45....

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION